Emerging retatrutide, a dual -action drug targeting simultaneously GLP-1 and GIP receptors, is generating considerable interest within the healthcare community. Preliminary clinical trials have demonstrated significant decreases in physical weight and gains in metabolic markers for individuals with excess weight . Scientists believe this unique app